Patents by Inventor Matthew Bio

Matthew Bio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20230301974
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: May 8, 2023
    Publication date: September 28, 2023
    Applicant: AMGEN INC.
    Inventors: Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. MCGEE, Filisaty VOUNATSOS, Sean H. WIEDEMANN, Sarah WORTMAN
  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20220280496
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: October 13, 2021
    Publication date: September 8, 2022
    Applicant: AMGEN INC.
    Inventors: Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. MCGEE, Filisaty VOUNATSOS, Sean H. WIEDEMANN, Sarah WORTMAN
  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20200281912
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: October 25, 2019
    Publication date: September 10, 2020
    Applicant: AMGEN IINC.
    Inventors: Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. MCGEE, Filisaty VOUNTSOS, Sean H. WIEDEMANN, Sarah WORTMAN
  • Polymorphic forms and co-crystals of a c-Met inhibitor
    Patent number: 10344041
    Abstract: Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: July 9, 2019
    Assignee: Amgen, Inc.
    Inventors: David Bauer, Matthew Bio, Melanie Cooke, Katrina W. Copeland, Matthew Peterson, Michele Potashman, Roman Shimanovich, Helming Tan
  • POLYMORPHIC FORMS AND CO-CRYSTALS OF A C-MET INHIBITOR
    Publication number: 20180244696
    Abstract: Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.
    Type: Application
    Filed: April 30, 2018
    Publication date: August 30, 2018
    Inventors: David BAUER, Matthew BIO, Melanie COOKE, Katrina W. COPELAND, Matthew PETERSON, Michele POTASHMAN, Roman SHIMANOVICH, Helming TAN
  • Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof
    Patent number: 10053452
    Abstract: The present invention relates to crystalline forms and co-crystal forms of pharmaceutically acceptable salts of the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine (AMG 900, and pharmaceutical compositions comprising said crystalline and co-crystal forms thereof. The invention further provides uses of the crystalline forms and compositions, to treat cancer, including various types of solid tumors and hematologic cancer including myeloma and leukemia.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: August 21, 2018
    Assignee: AMGEN INC.
    Inventors: Mary Chaves, Matthew Bio, Matthew Peterson
  • Polymorphic forms and co-crystals of a c-Met inhibitor
    Patent number: 9981988
    Abstract: Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 29, 2018
    Assignee: AMGEN INC.
    Inventors: David Bauer, Matthew Bio, Melanie Cooke, Katrina W. Copeland, Matthew Peterson, Michele Potashman, Roman Shimanovich, Helming Tan
  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20180092898
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: November 22, 2017
    Publication date: April 5, 2018
    Applicant: AMGEN INC.
    Inventors: Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. MCGEE, Filisaty VOUNATSOS, Sean H. WIEDEMANN, Sarah WORTMAN
  • Processes of making and crystalline forms of a MDM2 inhibitor
    Patent number: 9855259
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: January 2, 2018
    Assignee: Amgen Inc.
    Inventors: Matthew Bio, Sebastien Caille, Brian Cochran, Yuanqing Fang, Filisaty Vounatsos, Sarah Wortman
  • Processes of making and crystalline forms of a MDM2 inhibitor
    Patent number: 9801867
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: October 31, 2017
    Assignee: Amgen Inc.
    Inventors: Matthew Bio, Sebastien Caille, Brian Cochran, Yuanqing Fang, Brian M. Fox, Brian S. Lucas, Lawrence R. McGee, Filisaty Vounatsos, Sean H. Wiedemann, Sarah Wortman
  • Method for the preparation of [1,2,4]-triazolo[4,3-a]pyridines
    Patent number: 9643984
    Abstract: Disclosed herein are methods for preparing [1,2,4]triazolo[4,3-a]pyridines, particularly (R)-6-(1-(8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, and precursors thereof, such as a method comprising reacting (R)—N-(3-fluoro-5-(1methyl-1H-pyrazol-4-yl) pyridin-2-yl)-2-(3-(2-methoxyethoxy)-5-oxo-1,6-naphthyridin-6(5H)yl) propanehydrazide (“HYDZ”): (HYDZ) under conditions sufficient to form (R)-6-(1-(8-fluoro-6-(1-methyl-IH-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (“A”): (A)
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: May 9, 2017
    Assignee: AMGEN INC.
    Inventors: Matthew Bio, Eric Fang, Jacqueline E. Milne, Sean Wiedemann, Ash Wilsily
  • Processes of making and crystalline forms of a MDM2 inhibitor
    Patent number: 9623018
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: April 18, 2017
    Assignee: Amgen Inc.
    Inventors: Matthew Bio, Sebastien Caille, Yuanqing Fang, Brian M. Fox, Brian S. Lucas, Lawrence R. McGee, Sean H. Wiedemann
  • POLYMORPHIC FORMS AND CO-CRYSTALS OF A C-MET INHIBITOR
    Publication number: 20170029443
    Abstract: Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.
    Type: Application
    Filed: October 14, 2016
    Publication date: February 2, 2017
    Inventors: David BAUER, Matthew BIO, Melanie COOKE, Katrina W. COPELAND, Matthew PETERSON, Michele POTASHMAN, Roman SHIMANOVICH, Helming TAN
  • METHOD FOR THE PREPARATION OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES
    Publication number: 20160347769
    Abstract: Disclosed herein are methods for preparing [1,2,4]triazolo[4,3-a]pyridines, particularly (R)-6-(1-(8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, and precursors thereof, such as a method comprising reacting (R)—N-(3-fluoro-5-(1methyl-1H-pyrazol-4-yl) pyridin-2-yl)-2-(3-(2-methoxyethoxy)-5-oxo-1,6-naphthyridin-6(5H)yl) propanehydrazide (“HYDZ”): (HYDZ) under conditions sufficient to form (R)-6-(1-(8-fluoro-6-(1-methyl-IH-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (“A”): (A)
    Type: Application
    Filed: June 24, 2014
    Publication date: December 1, 2016
    Inventors: Matthew BIO, Eric FANG, Jacqueline E. MILNE, Sean WIEDEMANN, Ash WILSILY
  • CRYSTALLINE FORMS OF N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL -2-THIENYL)-1-PHTHALAZINAMINE SALTS AND USES THEREOF
    Publication number: 20160304504
    Abstract: The present invention relates to crystalline forms and co-crystal forms of pharmaceutically acceptable salts of the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine (AMG 900, and pharmaceutical compositions comprising said crystalline and co-crystal forms thereof. The invention further provides uses of the crystalline forms and compositions, to treat cancer, including various types of solid tumors and hematologic cancer including myeloma and leukemia.
    Type: Application
    Filed: November 25, 2014
    Publication date: October 20, 2016
    Inventors: Mary CHAVES, Matthew BIO, Matthew PETERSON
  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20160287570
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: June 7, 2016
    Publication date: October 6, 2016
    Applicant: AMGEN INC.
    Inventors: Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Filisaty VOUNATSOS, Sarah WORTMAN
  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20160289243
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: June 7, 2016
    Publication date: October 6, 2016
    Applicant: AMGEN INC.
    Inventors: Matthew BIO, Sebastien CAILLE, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. McGEE, Sean H. WIEDEMANN
  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20160289190
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: June 7, 2016
    Publication date: October 6, 2016
    Applicant: AMGEN INC.
    Inventors: Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Brian M. FOX, Brian S. LUCAS, Lawrence R. McGEE, Filisaty VOUNATSOS, Sean H. WIEDEMANN, Sarah WORTMAN
  • PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR
    Publication number: 20160264526
    Abstract: The present invention provides processes for making 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid as well as intermediates and processes for making the intermediates. Also provided are crystalline forms of the compound and the intermediates.
    Type: Application
    Filed: May 24, 2016
    Publication date: September 15, 2016
    Applicant: AMGEN INC.
    Inventors: Matthew BIO, Sebastien CAILLE, Brian COCHRAN, Yuanqing FANG, Filisaty VOUNATSOS, Sarah WORTMAN
  • METHOD FOR THE PREPARATION OF THIADIAZOLES
    Publication number: 20160221985
    Abstract: The present invention relates to processes for preparing protected glyceraldehydes, such as (hydroxy)methanesulfonates. In addition, the invention relates to thiadiazoles, particularly 3-diooxolanyl-thiadiazoles.
    Type: Application
    Filed: February 1, 2016
    Publication date: August 4, 2016
    Inventors: Eric A. Bercot, Matthew Bio, Johann Chan, John Colyer, Yuanqing Fang, Steven Mennen, Robert R. Milburn, Jason Tedrow, Babak Riahi